Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Anhedonia
Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial
Posted innews Psychiatry

Systemic Inflammation as a Modulator of Anhedonia in Major Depressive Disorder: Insights from an LPS Challenge Trial

Posted by MedXY By MedXY 10/31/2025
This RCT reveals that adults with major depressive disorder and elevated systemic inflammation exhibit heightened anhedonic responses to an inflammatory challenge, highlighting inflammation's role in depression symptomatology.
Read More
Azetukalner: A Novel KV7 Potassium Channel Opener Shows Promise in Treating Major Depressive Disorder
Posted innews Psychiatry

Azetukalner: A Novel KV7 Potassium Channel Opener Shows Promise in Treating Major Depressive Disorder

Posted by MedXY By MedXY 10/21/2025
Azetukalner, a KV7 potassium channel opener, demonstrated clinically meaningful antidepressant effects and significant improvement in anhedonia in adults with major depressive disorder in a 6-week randomized trial, supporting further development.
Read More
  • SAIA-MH Strategy Boosts Mental Health Outcomes in Mozambique: A Breakthrough in Low-Resource Settings
  • Low-Calorie, Low-Protein Feeding in Shock: No Harm to Kidneys, NUTRIREA-3 Analysis Confirms
  • Language Barriers and Delirium Detection: Study Reveals Critical Disparities in ICU Care for Spanish-Speaking Patients
  • Observation Reduces CT Use in Pediatric Blunt Abdominal Trauma Without Missing Critical Injuries
  • Digital Mental Health Interventions Show Promise for Black and Female Health Care Workers
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in